-
May 27, 2022, 09:12 AM
by
BOC Sciences offers professional stable isotope labeling services to support worldwide partners from preclinical to commercial stages.
Full story
-
May 27, 2022, 09:12 AM
by
Today, BOC Sciences released a complete set of virtual screening solutions to help partners maximize the diversity of hits using its ultra-large-scale purchasable compound libraries.
Full story
-
May 27, 2022, 09:12 AM
by
BOC Sciences today unveiled access to its comprehensive set of PROTAC in vitro evaluation services for biopharmaceutical clients and partners to expedite their PROTAC development from preclinical studies to clinical trials.
Full story
-
May 27, 2022, 09:12 AM
by
Creative Peptides supplies standard Fmoc- and Boc-PNA monomers that can be ordered in large quantities with high purity, solubility, and reactivity.
Full story
-
May 26, 2022, 09:30 AM
by
As a reliable source for versatile catalysts, Alfa Chemistry Catalysts today announces that it has launched a rich of collection of asymmetric organocatalysts, including chiral amines, chiral amino acids, chiral ammonium salts, chiral bicyclic guanidines, chiral diols, chiral imidazolidinones, chiral isothioureas, chiral n-heterocyclic carbenes (NHC), chiral oxazaborolidines, chiral sulfonic acids, cinchona alkaloids, and prolines, proline analogs. All can be used to accelerate different types of chemical reactions for research and production, whereas all are of high purity and of high-popularity among consumers.
Full story
-
May 26, 2022, 09:27 AM
by
Full story
-
May 26, 2022, 09:27 AM
by
Full story
-
May 26, 2022, 01:00 AM
by
User Not Found
Bio-IT World | Proscia launches an automated quality-control application that leverages artificial intelligence to improve drug development; an end-to-end software and data management package aids antibody discovery; ArisGlobal acquires BI’s analytic system; a data cloud is used for increased statistical analysis efficiency; new products from SCIEX and Dotmatics, and more.
Full story
-
May 25, 2022, 13:14 PM
by
uMotif – the patient-first data capture and decentralized clinical trials platform – announces $25.5m of new investment from a fund managed by Athyrium Capital Management
LONDON and NEW YORK, May 25, 2022-- uMotif today announced a new investment of $25.5m from a fund managed by Athyrium Capital Management, LP, the New York-based investment firm. The new funding will support continued scale up of uMotif's unique patient-first software platform for clinical research.
Full story
-
May 25, 2022, 09:10 AM
by
CD BioSciences introduces comprehensive solutions for GPCR expression based on various strategies and technique platforms to facilitate customers’ cutting-edge programs.
Full story
-
May 25, 2022, 09:10 AM
by
STEMart expands its Biocompatibility Testing services and introduces biocompatibility evaluation of breathing gas pathways in medical devices.
Full story
-
May 25, 2022, 09:10 AM
by
Amerigo Scientific now introduces HHD Broth to the life science research community.
Full story
-
May 25, 2022, 09:10 AM
by
Creative Diagnostics recently introduces comprehensive services for antibody-dependent enhancement (ADE) assay.
Full story
-
May 25, 2022, 01:00 AM
by
User Not Found
Bio-IT World| Funding for data protection and security platforms, autologous cell therapies, rapid DNA sequencing, and more.
Full story
-
May 24, 2022, 14:14 PM
by
HealthSparq Annual Consumer Survey Reveals Strong Support for Price Transparency Government Mandates
Full story
-
May 24, 2022, 09:26 AM
by
Full story
-
May 24, 2022, 09:26 AM
by
MMS Holdings Inc. (MMS) – a data-focused contract research organization (CRO) – announced a collaboration with THREAD® as its partner of choice for its decentralized clinical trial platform (DCT) and DCT-enabled services, solidifying MMS as a full-service DCT provider. The THREAD partnership is one initiative of many at MMS dedicated to accelerating a path toward adopting more patient-focused clinical trials
Full story
-
May 24, 2022, 09:26 AM
by
The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity® Reports: Biosimilars 2022. The new report features interviews with leaders of biosimilars companies who give their unique insights into the challenges and opportunities facing this fast-growing sector and the leadership needed to grow the industry, including the power of creating strong in-house knowledge and evaluating where this talent already exists.
Full story
-
May 24, 2022, 09:26 AM
by
Full story
-
May 24, 2022, 09:26 AM
by
Full story